Our Publications

AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma

Fukuda K, Okamura K, Riding RL, Fan X, Afshari K, Haddadi NS, McCauley SM, Guney MH, Luban J, Funakoshi T, Yaguchi T, Kawakami Y, Khvorova A, Fitzgerald KA, Harris JE. AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma. J Exp Med(2021) 218:e20200962.

Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo

Richmond J, Strassner JP, Zapata L Jr., Garg M, Riding RL, Refat MA, Fan X, Azzolino V, Tovar-Garza A, Tsurushita N, Pandya AG, Tso JY, and Harris JE. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Science Transl. Med. (2018) 10:1-9.

CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo

Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su M, Zhou Y, Deng A, Hunter CA, Luster AD, and Harris JE. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Science Transl. Med. (2014) 6(223): 1-10. PMCID: 4086941

CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice

Richmond JM, Masterjohn E, Chu R, Tedstone J, Youd ME, Harris JE. CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice. J. Invest. Dermatol. (2017) 137: 982-5.

JAK inhibition prevents bleomycin-induced fibrosis in mice and is effective in morphea patients

Damsky W, Patel D, Garelli CJ, Garg M, Wang A, Dresser K, Deng A, Harris JE, Richmond J, King B. JAK inhibition prevents bleomycin-induced fibrosis in mice and is effective in morphea patients. JID (2020) 140: 1446-49.

JAK inhibitors reverse vitiligo in mice but do not deplete skin resident memory T cells

Azzolino V, Zapata L, Garg M, Gjoni M, Riding RL, Strassner JP, Richmond JM, Harris JE. JAK inhibitors reverse vitiligo in mice but do not deplete skin resident memory T cells. JID(2020) 141: 182-184.

Keratinocyte-derived chemokines orchestrate T cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J. Invest

Richmond JM, Essien KI, Bangari DS, Currimbhoy SD, Groom JR, Pandya AG, Youd ME, LusterAD, Harris JE. Keratinocyte-derived chemokines orchestrate T cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J. Invest. Dermatol. (2017) 137: 350-8.

Keratinocyte-tethering modification for biologics enables location-precise treatment in mouse vitiligo

Hsueh YC, Wang Y, Riding RL, Catalano DE, Lu YJ, Richmond JM, Siegel DL Rusckowski M, Stanley JR, and Harris JE. Keratinocyte-tethering modification for biologics enables location-precise treatment in mouse vitiligo. J. Invest. Dermatol. (2022) 142:3294-3303.

Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata

Harris JE, Rashighi M, Nguyen N, Jabbari A, Clynes R, Christiano AM, Mackay-Wiggan J. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata. J. Am. Acad. Derm. (2016) 74: 370-71. PMCID: 4718770.

RNAi-based modulation of IFN-γ signaling in skin

Tang Q, Sousa J, Echeverria D, Fan X, Hsueh YC, Afshari K, MeHugh N, Cooper DA, Vangjeli L, Monopoli K, Okamura K, Biscans A, Clauss A, Harris JE, and Khvorova A. RNAi-based modulation of IFN-γ signaling in skin. Mol Therapy (2022) 30:2709-2721.